hVIVO Plc (HVO.L) Announced the successful completion of an RSV human challenge study conducted in older adults, aged 60-75 years. The study was conducted at hVIVO's specialist clinical facility in London. The study demonstrated that an RSV challenge model can be conducted safely in a population of 60-75 years of age. The study, which extends hVIVO's commercial provision beyond the established RSV human challenge model in 18-60 year olds, comprised volunteers who were residential in hVIVO's state of the art human challenge clinical unit for a period of approximately 2 weeks after being inoculated with hVIVO's GMP-manufactured RSV Memphis 37 Challenge virus strain.
RNS Number: 9575 H hVIVO plc 06 August 2019 RNS REACH. London, UK- 6 August 2019: hVIVO plc, an industry leading clinical development services business pioneering human disease models based upon viral challenge, announces the successful completion of an RSV human challenge study conducted in older adults, aged 60-75 years. The study was conducted at hVIVO's...
hVIVO Plc (HVO.L) Announced that it confirms that AGS-v PLUS, an experimental vaccine designed to protect against many different mosquito-borne diseases, will be tested in a Phase 1 clinical trial by the NIH at the University of Maryland School of Medicine (NCT04009824). The vaccine, AGS-v PLUS, was developed by Imutex Limited, the company's 49% joint venture with the SEEK Group. The study received additional funding from the UK Department of Health and Social Care, managed by Innovate UK. Also, it announced that that Shelley Fraser, Finance Director and Company Secretary, is leaving the company and The Board has appointed Anesh Patel as Interim Finance Director and Company Secretary with immediate effect.
RNS Number: 2829 H hVIVO plc 31 July 2019. London, UK- 31 July 2019: hVIVO plc, an industry leading clinical development services business pioneering human disease models based upon viral challenge, announces that Shelley Fraser, Finance Director and Company Secretary, is leaving hVIVO. The Board has appointed Anesh Patel as Interim Finance Director and Company...
-The study received additional funding from the UK Department of Health and Social Care, managed by Innovate UK. London, UK, 31 July 2019: hVIVO plc, an industry leading clinical development services business pioneering human disease models based upon viral challenge, confirms that AGS-v PLUS, a n experimental vaccine designed to protect against many different...
London, UK, 25 July 2019: hVIVO plc, an industry leading clinical development services business pioneering human disease models based upon viral and allergen challenge, announces that, following the exercise of employee share options by an ex-employee, application has been made to AIM for the admission of 6,238 new ordinary shares of 5 pence each..
London, UK, 25 July 2019: hVIVO plc, an industry leading clinical development services business pioneering human disease models based upon viral and allergen challenge, announces that, following the exercise of employee share options by an ex-employee, application has been made to AIM for the admission of 42,008 new ordinary shares of 5 pence each..
London, UK, 16 July 2019: hVIVO plc, an industry leading clinical development services business pioneering human disease models based upon viral and allergen challenge, announces that, following the exercise of employee share options by an ex-employee, application has been made to AIM for the admission of 50,037 new ordinary shares of 5 pence each..
RNS Number: 9894 E hVIVO plc 09 July 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 9447 E hVIVO plc 09 July 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
London, UK, 26 June 2019: hVIVO plc, an industry leading clinical development services business pioneering human disease models based upon viral and allergen challenge, announces that, following the exercise of employee share options by an ex-employee, application has been made to AIM for the admission of 6,238 new ordinary shares of 5 pence each..
hVIVO Plc (HVO.L) Announced that Enanta Pharmaceuticals, Inc. has revealed positive topline results from an RSV challenge study. The study demonstrated that Enanta's novel N-protein inhibitor, EDP-938, achieved highly statistically significant (p<0.001) reductions in viral load and in resolution of clinical symptoms compared to placebo in healthy adults infected with respiratory syncytial virus (RSV). The study was conducted at the company’s specialist clinical facility in London, using its industry leading RSV challenge study protocol.
RNS Number: 3913 C hVIVO plc 17 June 2019 hVIVO plc. London, UK- 17 June 2019: hVIVO plc, an industry leading clinical development services business pioneering human disease models based upon viral challenge, acknowledges the announcement by Enanta Pharmaceuticals, Inc. of positive topline results from an RSV challenge study. The study demonstrated that...
London, UK, 14 June 2019: hVIVO plc, an industry leading clinical development services business pioneering human disease models based upon viral and allergen challenge, announces that, following the exercise of employee share options by an ex-employee, application has been made to AIM for the admission of 15,344 new ordinary shares of 5 pence each..
London, UK, 31 May 2019: hVIVO plc, an industry leading clinical development services business pioneering human disease models based upon viral and allergen challenge, announces that, all resolutions proposed at its Annual General Meeting, held at 10.00 am on 30 May 2019, were duly passed. Based in the UK, market leader hVIVO has conducted more than 50 clinical...
London, UK, 21 May 2019: hVIVO plc, an industry leading clinical development services business pioneering human disease models based upon viral and allergen challenge, announces that, following the exercise of employee share options by an ex-employee, application has been made to AIM for the admission of 23,465 new ordinary shares of 5 pence each..
RNS Number: 2431 X hVIVO plc 26 April 2019 hVIVO plc. London, UK- 26 April 2019: hVIVO plc, announces that the following documents have been sent to shareholders. The AGM is scheduled to be held at 10.00 am BST on Thursday 30 May 2019 on 3 rd Floor, Queen Mary BioEnterprises Innovation Centre, 42 New Road, London, E1 2 AX..
hVIVO (HVO.L) 27.25p £23.64m hVIVO, an industry leading clinical development services business pioneering human disease models based upon viral challenge, announced its preliminary results for the year ended 31 Dec 2018. Revenue & Other Income up 10.5% to £13.6m (2017: £12.3m) Adjusted Loss Before Tax down 27.6% to £9.6m (2017: £13.2m) Loss Before Tax - £18.9m (2017: £14.8m) Cash and cash equivalents of £13.4m (2017: £20.3m) Research and development expense down 21% to £4.8m (2017: £6.1m) Current cost reduction programmes are forecasted to deliver improvements which will reduce operating expense by a total of £3.9m, across 2018, 2019 and 2020 Re-focussed services business model with strong pipeline of contract opportunities Good progress on business turnaround, R&D expense significantly reduced and focussed specifically on opportunities to support the enhancement of our development services Cost base and expenditure reductions implemented to support future growth and provide a pathway to cash generation Positive Phase IIb FLU-v results
hVIVO Plc (HVO.L) Announced, in its preliminary results for the year ended 31 December 2018, that revenues rose to £11.0 million from £10.9 million recorded in the previous year. Loss after tax widened to £16.8 million from £12.96 million.
hVIVO Plc
HVO.L
hVIVO Plc
Bid
-
-
-
Ask
  • High
    -
  • OPEN
    -
  • VOL
    -
  • MKT CAP
    -m
  • LOW
    -
  • CLOSE
    -
  • AVG VOL
    -
  • SHARES IN ISSUE
    82.30M
Watchlist